Supervising the drug price and investigating the cost price

December 9th, 2019 | by

On December 6th, the National Medical Insurance Bureau issued the “Opinions on Supervising the Drug Price.” The “Opinion” indicated that a pricing system that depends on the market should be encouraged, and the centralised procurement with defined quantities, of which the drug price depends on the quantities and the bidding process combines with the procurement, should be further implemented. The “Opinion” also stipulated that a pre-warning system of abnormal drug price movements and an investigation system of the cost price of drugs should be established as well.

国家医保局发布文件:监管药品价格 调查成本

来源:医药网 2019.12.09



Leave a Reply

Your email address will not be published. Required fields are marked *